# A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

> **NCT03241173** · PHASE1,PHASE2 · COMPLETED · sponsor: **Incyte Biosciences International Sàrl** · enrollment: 52 (actual)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** INCAGN01949
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03241173
- **Lead sponsor:** Incyte Biosciences International Sàrl
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-09
- **Primary completion:** 2019-09-17
- **Final completion:** 2019-09-17
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2022-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03241173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03241173, "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03241173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*